Moderate to Severe Refractory Autoimmune Diseases
1 clinical trials · Condition
◉ Watch Moderate to Severe Refractory Autoimmune Diseases
| Record | Firm | Date |
|---|---|---|
| A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate to Severe Refractory Autoimmune Diseases (NCT07614191) | Vivacta Biotechnology (Shanghai) Co., Ltd. | 2026-05-25 |
Track Moderate to Severe Refractory Autoimmune Diseases automatically
Every clearance here is in the API, with alerts when new ones post.